Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer

NCT01298570 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT01298570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01298570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2011
Completion date
October 2, 2020
Enrollment
181 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic